Arcus Biosciences Stock Buy Hold or Sell Recommendation

RCUS Stock  USD 9.34  0.20  2.10%   
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Arcus Biosciences is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Arcus Biosciences given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Arcus Biosciences, the advice is generated through an automated system that utilizes algorithms and statistical models.
  
Check out Arcus Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.
Note, we conduct extensive research on individual companies such as Arcus and provide practical buy, sell, or hold advice based on investors' constraints. Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Execute Arcus Biosciences Buy or Sell Advice

The Arcus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Arcus Biosciences. Macroaxis does not own or have any residual interests in Arcus Biosciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Arcus Biosciences' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Arcus BiosciencesBuy Arcus Biosciences
Strong Sell

Market Performance

Very WeakDetails

Volatility

Not too volatileDetails

Hype Condition

Under hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

LowDetails

Economic Sensitivity

Almost mirrors the marketDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

PoorDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Possible ManipulatorDetails
For the selected time horizon Arcus Biosciences has a Mean Deviation of 2.71, Standard Deviation of 3.77 and Variance of 14.21
We provide trade advice to complement the prevailing expert consensus on Arcus Biosciences. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Arcus Biosciences is not overpriced, please confirm all Arcus Biosciences fundamentals, including its number of shares shorted, current ratio, net asset, as well as the relationship between the ebitda and number of employees . Given that Arcus Biosciences has a number of shares shorted of 6.88 M, we suggest you to validate Arcus Biosciences market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Arcus Biosciences Trading Alerts and Improvement Suggestions

Arcus Biosciences generated a negative expected return over the last 90 days
Arcus Biosciences has high historical volatility and very poor performance
The company reported the previous year's revenue of 258 M. Net Loss for the year was (283 M) with loss before overhead, payroll, taxes, and interest of (190 M).
Arcus Biosciences currently holds about 1.05 B in cash with (170 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Arcus Biosciences has a poor financial position based on the latest SEC disclosures
Over 83.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: Arcus Biosciences, Inc. Among Top Insider Purchases Last Month

Arcus Biosciences Returns Distribution Density

The distribution of Arcus Biosciences' historical returns is an attempt to chart the uncertainty of Arcus Biosciences' future price movements. The chart of the probability distribution of Arcus Biosciences daily returns describes the distribution of returns around its average expected value. We use Arcus Biosciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Arcus Biosciences returns is essential to provide solid investment advice for Arcus Biosciences.
Mean Return
-0.86
Value At Risk
-6.29
Potential Upside
3.18
Standard Deviation
3.77
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Arcus Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Arcus Stock Institutional Investors

The Arcus Biosciences' institutional investors refer to entities that pool money to purchase Arcus Biosciences' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
Shares
Bnp Paribas Investment Partners Sa2024-12-31
1.5 M
Parkman Healthcare Partners Llc2024-12-31
1.3 M
Geode Capital Management, Llc2024-12-31
1.2 M
Millennium Management Llc2024-12-31
924.4 K
Decheng Capital Llc2024-12-31
808.8 K
Braidwell Lp2024-12-31
802.1 K
Charles Schwab Investment Management Inc2024-12-31
579.6 K
Suvretta Capital Management, Llc2024-12-31
576.2 K
Morgan Stanley - Brokerage Accounts2024-12-31
549.9 K
Blackrock Inc2024-12-31
9.7 M
Vanguard Group Inc2024-12-31
5.4 M
Note, although Arcus Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Arcus Biosciences Cash Flow Accounts

202020212022202320242025 (projected)
Investments(431.3M)(28.8M)(413M)213M(84M)(88.2M)
Change In Cash115.5M(22.7M)58M(79M)23M24.2M
Free Cash Flow108.1M(282.2M)426M(330M)(176M)(167.2M)
Depreciation4.2M3.8M6M8M10M5.3M
Other Non Cash Items(46K)3.5M11M(9M)5M5.3M
Capital Expenditures3.1M26.1M12M24M6M10.6M
Net Income(122.9M)52.8M(267M)(307M)(283M)(268.9M)
End Period Cash Flow173.6M150.9M209M130M153M135.6M
Change To Netincome10.2M21.8M54.5M76M87.4M91.8M
Change To Inventory21.3M14.1M(704M)(15M)(13.5M)(14.2M)

Arcus Biosciences Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Arcus Biosciences or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Arcus Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Arcus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
-0.75
β
Beta against Dow Jones1.09
σ
Overall volatility
3.76
Ir
Information ratio -0.2

Arcus Biosciences Volatility Alert

Arcus Biosciences exhibits very low volatility with skewness of -0.77 and kurtosis of 4.04. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Arcus Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Arcus Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Arcus Biosciences Fundamentals Vs Peers

Comparing Arcus Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Arcus Biosciences' direct or indirect competition across all of the common fundamentals between Arcus Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Arcus Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Arcus Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Arcus Biosciences by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Arcus Biosciences to competition
FundamentalsArcus BiosciencesPeer Average
Return On Equity-0.6-0.31
Return On Asset-0.17-0.14
Profit Margin(1.10) %(1.27) %
Operating Margin(3.96) %(5.51) %
Current Valuation70.56 M16.62 B
Shares Outstanding105.84 M571.82 M
Shares Owned By Insiders5.51 %10.09 %
Shares Owned By Institutions83.48 %39.21 %
Number Of Shares Shorted6.88 M4.71 M
Price To Earning27.69 X28.72 X
Price To Book2.04 X9.51 X
Price To Sales3.83 X11.42 X
Revenue258 M9.43 B
Gross Profit(190 M)27.38 B
EBITDA(269 M)3.9 B
Net Income(283 M)570.98 M
Cash And Equivalents1.05 B2.7 B
Cash Per Share14.48 X5.01 X
Total Debt48 M5.32 B
Debt To Equity0.17 %48.70 %
Current Ratio6.22 X2.16 X
Book Value Per Share5.26 X1.93 K
Cash Flow From Operations(170 M)971.22 M
Short Ratio5.86 X4.00 X
Earnings Per Share(3.14) X3.12 X
Target Price32.55
Number Of Employees62718.84 K
Beta1.36-0.15
Market Capitalization988.55 M19.03 B
Total Asset1.15 B29.47 B
Retained Earnings(1.13 B)9.33 B
Working Capital790 M1.48 B
Net Asset1.15 B
Note: Insider Trading [view details]

Arcus Biosciences Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Arcus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Arcus Biosciences Buy or Sell Advice

When is the right time to buy or sell Arcus Biosciences? Buying financial instruments such as Arcus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Arcus Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run ISP Thematic Idea Now

ISP
ISP Theme
Internet Service Providers (ISP) companies and IT providers specializing in internet technologies. The ISP theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ISP Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Arcus Stock Analysis

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.